Prescriber Scope of Practice for Narcolepsy in Texas

If you’re a psychiatrist or PMHNP considering treating narcolepsy patients remotely, you’re navigating one of the trickiest corners of telehealth regulation. Narcolepsy treatment relies heavily on Schedule II stimulants (Adderall, Ritalin) and other controlled substances (modafinil, sodium oxybate) — medications that sit squarely in the crosshairs of federal and state prescribing rules.

Here’s what you actually need to know about prescribing narcolepsy meds via telehealth in 2026, stripped of the legal jargon.

The Bottom Line Up Front

Yes, you can prescribe narcolepsy medications via telehealth right now — but it’s temporary, complicated, and state-dependent.

Through December 31, 2026, the DEA’s COVID-era flexibility allows you to prescribe controlled substances (including Schedule II stimulants) via telemedicine without an initial in-person visit. That’s the good news. The catch? This is a temporary extension while the DEA finalizes permanent rules, and several states impose their own restrictions that can override federal allowances.

For narcolepsy specifically, you’re dealing with a neurological sleep disorder (not a psychiatric condition), which matters in states like Florida that explicitly prohibit Schedule II telehealth prescribing except for psychiatric indications. In Texas, NPs can’t prescribe Schedule II medications at all in outpatient settings. And even in permissive states, you’ll need to coordinate in-person sleep studies for diagnosis confirmation.

Let’s break down what works, what doesn’t, and how to build a compliant telehealth practice around narcolepsy care.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Federal Rules: The DEA’s Telehealth Extension (And What Comes Next)

The Ryan Haight Act Still Exists (Technically)

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was designed to prevent online pill mills. It requires at least one in-person medical evaluation before prescribing any controlled substance via telemedicine. No exceptions, no shortcuts — or at least, that was the law.

In practice, this meant pre-COVID psychiatrists couldn’t start someone on Adderall or modafinil after just a video call. You needed that patient in your office at least once.

COVID Changed Everything (For Now)

In March 2020, the DEA waived the in-person requirement entirely. Suddenly, you could evaluate a patient via video (or even phone in some cases) and prescribe Schedule II–V medications remotely, as long as the prescription was legitimate and you met all other requirements (state license, DEA registration, standard of care).

That waiver was supposed to end with the Public Health Emergency in May 2023. Instead, facing massive pushback from providers and patients, the DEA has extended it four times. The current extension runs through December 31, 2026.

What this means for narcolepsy providers: You can diagnose narcolepsy via telehealth, coordinate necessary testing (polysomnogram, MSLT), and prescribe stimulants or other controlled meds without ever meeting the patient in person — if you’re practicing in a state that allows it.

Permanent Rules Are Coming (Eventually)

The DEA proposed permanent telehealth rules in 2023 that would have required an in-person visit after an initial 30-day telemedicine prescription for Schedule II drugs. Over 38,000 public comments pushed back hard, and the DEA shelved those rules to reconsider.

As of February 2026, we’re still waiting. The only finalized telehealth rules the DEA has issued are narrow: one expanding buprenorphine prescribing for opioid use disorder, another allowing VA system patients to continue controlled-substance care via telemedicine.

Reality check: When permanent rules do arrive (likely late 2026 or 2027), expect some middle ground. Probably not the draconian ‘in-person after 30 days’ originally proposed, but likely some requirement — maybe an in-person exam for new patients within 90 days, or limits on initial quantities, or a special telemedicine registration process.

Plan accordingly: If you’re building a narcolepsy telehealth practice, assume you’ll eventually need a hybrid model — video visits for ongoing management, but partnerships with local clinics or sleep centers for initial diagnostic workups and periodic in-person checks.

State-by-State Reality: Where You Can (and Can’t) Prescribe Narcolepsy Meds Remotely

Federal law sets the floor. State law adds the complications.

Florida: The Big Exception

Florida explicitly bans Schedule II prescribing via telehealth — except for treating psychiatric disorders, inpatient care, hospice, or nursing home residents (Fla. Stat. §456.47).

Narcolepsy is a neurological sleep disorder, not a psychiatric condition. That means a Florida telepsychiatrist cannot legally prescribe Adderall or other Schedule II stimulants for narcolepsy via telemedicine, even under the current DEA waiver.

Workarounds:

• Prescribe modafinil or armodafinil (Schedule IV) instead — those aren’t covered by Florida’s Schedule II telehealth ban
• Require at least one in-person visit to start Schedule II medications
• Partner with a local physician or sleep clinic for the initial prescription, then manage via telehealth

For PMHNPs in Florida, it gets worse: even if treating a psychiatric condition (where telehealth Schedule II is allowed), NPs are limited to 7-day supplies of Schedule II medications unless they’re a certified ‘psychiatric nurse’ treating a mental health disorder. That 7-day cap doesn’t help with narcolepsy either.

Bottom line: Florida is hostile territory for telehealth narcolepsy care involving stimulants. Many providers there default to modafinil or hybrid models.

Texas: NPs Are Shut Out of Schedule II Entirely

Texas allows telehealth establishment of a physician-patient relationship via video, and psychiatrists can prescribe controlled substances remotely under the DEA waiver.

But Texas NPs and PAs cannot prescribe Schedule II medications in outpatient settings, period. The only exceptions are hospital inpatient admissions (≥24 hours), emergency departments, or hospice care — and even then, the Rx must be filled at the facility pharmacy.

What this means: A Texas PMHNP treating narcolepsy can prescribe modafinil (Schedule IV) under a physician delegation agreement, but cannot prescribe Adderall, Ritalin, or other Schedule II stimulants at all. The supervising physician would have to write those prescriptions.

If you’re building a telehealth narcolepsy practice in Texas, you need psychiatrists or MDs to handle Schedule II prescribing. NPs can manage the ongoing care (titration, side effects, follow-ups), but the MD writes the controlled scripts.

Also in Texas: Telehealth prescribing requires two-way audio-visual communication (live video). A phone call alone won’t cut it for controlled substances.

New York: Aligned with Federal Rules (For Now)

New York finalized regulations in May 2025 that require an in-person exam before prescribing controlled substances via telehealth — unless you meet a federal or state exception.

The key exception: prescribing is allowed if done ‘in accordance with applicable federal law.’ Since the DEA waiver currently permits telehealth controlled-substance prescribing, New York defers to that.

Practically: A New York psychiatrist or independent PMHNP can prescribe narcolepsy medications via telehealth right now, no in-person visit required. When the DEA waiver expires or new federal rules impose restrictions, New York will automatically align with whatever those rules require.

New York is also a full practice state for experienced NPs (3,600+ hours). Independent PMHNPs can diagnose narcolepsy, order sleep studies, and prescribe Schedule II–V medications entirely on their own license — no physician oversight needed.

Compliance notes: You must check the I-STOP PDMP before every controlled substance prescription and use e-prescribing (mandated in NY).

California: NP Independence Is Here (If You Qualify)

California implemented AB 890 in 2023, creating pathways for NP independent practice. Qualified NPs (≥4,600 hours or 3 years of supervised experience) can obtain full practice authority, including Schedule II prescriptive authority.

For narcolepsy: A California PMHNP with full practice certification can diagnose and treat narcolepsy independently, including prescribing stimulants. They need:

• Completion of required pharmacology education on controlled substances
• A furnishing number with Schedule II authority from the California Board of Nursing
• DEA registration

California has no state-imposed telehealth restrictions on controlled substances beyond federal law. You can establish the patient relationship via video and prescribe remotely.

The catch: You must check the CURES PDMP before prescribing Schedule II–IV for the first time, and at least every 4 months if therapy continues. California aggressively monitors this — compliance isn’t optional.

Pennsylvania: Physician Collaboration Required, But Doable

Pennsylvania requires all NPs (CRNPs) to have a collaborative agreement with a physician. There’s no independent practice for NPs yet, despite ongoing legislative efforts.

Schedule II prescribing: A Pennsylvania CRNP can prescribe Schedule II medications if their collaborating physician approves it in the agreement. However, there’s a 30-day supply limit — prescriptions beyond that require physician consultation and patient re-evaluation.

For ongoing narcolepsy care: This means the collaborating physician needs to be involved periodically, especially if the patient is on high doses or long-acting stimulants. It’s not a dealbreaker, but it adds administrative overhead.

Telehealth: Pennsylvania has no specific prohibition on controlled substances via telehealth. You can prescribe remotely under the DEA waiver, with proper documentation and PDMP checks.

Illinois: Full Practice for Qualified NPs

Illinois allows NPs to achieve full practice authority after 4,000 hours of collaborative practice plus 250 hours of continuing education in their specialty.

Once an Illinois NP obtains FPA, they can prescribe Schedule II–V independently (after getting a Mid-Level Practitioner Controlled Substance License from the state, in addition to DEA registration).

Narcolepsy-specific: Illinois law requires NPs with FPA to have a ‘consultation relationship’ with a physician if prescribing benzodiazepines or opioids. Stimulants aren’t opioids, so that requirement likely doesn’t apply — meaning an FPA-NP could prescribe Adderall or other narcolepsy stimulants independently.

Compliance: Check the Illinois PMP before prescribing, and use e-prescribing (mandated since January 2023 for all controlled substances).

Psychiatrist vs PMHNP Scope: Who Can Do What?

Psychiatrists Have Maximum Authority (Everywhere)

If you’re a psychiatrist (MD/DO), you have full authority to diagnose narcolepsy and prescribe any necessary medication in all 50 states, as long as you:

• Hold a medical license in the patient’s state
• Have a DEA registration for the appropriate schedules
• Meet the state’s telehealth standards (usually video, proper exam, documentation)

The only state-level wrinkle is Florida’s telehealth ban on Schedule II for non-psychiatric conditions — but that applies equally to MDs and DOs.

PMHNPs Face State-Dependent Restrictions

Full Practice States (for experienced NPs):

• New York, California, Illinois — Independent PMHNPs can diagnose and treat narcolepsy, including Schedule II prescribing, with no physician oversight required

Reduced Practice States:

• Pennsylvania — NPs need physician collaboration and face 30-day Schedule II limits; doable but adds oversight
• Florida — Collaboration required, plus 7-day Schedule II limit (unless certified psychiatric nurse treating mental illness); narcolepsy doesn’t qualify

Restricted Practice States:

• Texas — NPs cannot prescribe Schedule II in outpatient settings at all; physician must write those prescriptions

The Narcolepsy Diagnosis Challenge

Here’s a practical issue that affects all providers: confirming a narcolepsy diagnosis typically requires:

• Polysomnography (overnight sleep study)
• Multiple Sleep Latency Test (MSLT)

These are in-person procedures done in sleep labs. You can’t diagnose narcolepsy purely via telehealth — you need to coordinate testing.

Strategies:

1. Referral networks: Partner with sleep centers in your target states to refer patients for diagnostic testing
2. Consultation model: See patients who already have a confirmed narcolepsy diagnosis from a neurologist or sleep specialist
3. Hybrid approach: Initial video evaluation → order sleep studies → follow-up video visit to review results and start treatment

This is where telehealth platforms like Klarity Health create value: they handle the coordination headaches (finding local testing sites, managing referrals, insurance verification) so you can focus on clinical care.

Medications You’ll Prescribe (And Their Regulatory Quirks)

Schedule II Stimulants

Medications: Methylphenidate (Ritalin, Concerta), amphetamine (Adderall), dextroamphetamine (Dexedrine)

Used for: Excessive daytime sleepiness in narcolepsy

Regulatory reality:

• Highest scrutiny under DEA rules (most affected by Ryan Haight Act)
• Some states (Florida, Texas for NPs) heavily restrict or ban via telehealth
• Require PDMP checks in all states
• E-prescribing mandated in most states (no paper scripts)
• High abuse potential means more documentation of medical necessity

Practical note: These are the bread-and-butter narcolepsy meds, but also the biggest regulatory headache for telehealth.

Schedule IV Wakefulness Agents

Medications: Modafinil (Provigil), armodafinil (Nuvigil)

Used for: Excessive daytime sleepiness (often first-line treatment)

Regulatory reality:

• Less restricted than Schedule II
• Not covered by Florida’s telehealth ban (only II and III are banned)
• Can be prescribed by NPs in all states (within scope of practice)
• Still require PDMP checks and e-prescribing

Strategy: In restrictive states like Florida, modafinil/armodafinil become your go-to for pure telehealth prescribing.

Schedule III Sodium Oxybate

Medications: Xyrem, Xywav (sodium oxybate)

Used for: Cataplexy and excessive daytime sleepiness in narcolepsy

Regulatory reality:

• FDA REMS program — you must be specially enrolled to prescribe
• Patients must use a centralized pharmacy (can’t be filled at local pharmacies)
• Extra documentation and monitoring required
• Subject to same telehealth rules as other controlled substances

Practical note: This is a niche medication for severe cases. The REMS enrollment is an administrative barrier, but the centralized pharmacy actually simplifies things (they handle distribution and patient education).

Compliance Checklist: How to Prescribe Narcolepsy Meds Legally via Telehealth

Before You Start

• [ ] State medical license in the patient’s state
• [ ] DEA registration with Schedule II authority (and physical address in the state, if required)
• [ ] State-specific controlled substance registration (New York, Illinois mid-level CS license for NPs, etc.)
• [ ] PDMP enrollment in each state where you’ll prescribe
• [ ] E-prescribing platform that meets DEA two-factor authentication requirements
• [ ] Malpractice insurance that covers telehealth and controlled substance prescribing
• [ ] Collaborative agreement (if required in your state as an NP)

For Each Patient Encounter

• [ ] Verify patient identity (photo ID, matching information)
• [ ] Document informed consent for telehealth (separate from general medical consent in many states)
• [ ] Conduct thorough evaluation via video (Texas explicitly requires video for controlled substances; phone alone isn’t sufficient in most states)
• [ ] Check state PDMP before prescribing (required before each controlled Rx in most states)
• [ ] Document clinical rationale for controlled medication (especially stimulants — note diagnosis, symptoms, failure of alternatives, monitoring plan)
• [ ] Coordinate diagnostic testing if diagnosis not yet confirmed (refer for sleep study)
• [ ] Use e-prescribing (mandated in IL, NY, CA, and many others)
• [ ] Schedule appropriate follow-up (more frequent initially for controlled substances — every 30-90 days is common)

State-Specific Requirements

Florida: Avoid Schedule II via telehealth for narcolepsy (use modafinil or require in-person)

Texas: Use video, not phone; ensure physician handles Schedule II if you’re an NP

New York: Check I-STOP PDMP; e-prescribing mandatory

California: Check CURES PDMP at first prescription and every 4 months

Pennsylvania: Document physician collaboration if you’re an NP; 30-day Schedule II limit

Illinois: Get mid-level CS license; check IL PMP before prescribing

The Economics of Telehealth Narcolepsy Care

Let’s talk about what no one else will: the business reality of treating narcolepsy patients remotely.

Why Narcolepsy Is Underserved

Narcolepsy affects about 1 in 2,000 people in the U.S. — roughly 200,000 patients. But the average time from symptom onset to diagnosis is 8-10 years.

Why? Two reasons:

1. Scarcity of specialists: Most narcolepsy is diagnosed and managed by sleep medicine specialists or neurologists. There aren’t enough of them, especially in rural areas.
2. Diagnostic complexity: You need access to a sleep lab for polysomnography and MSLT. Many patients can’t get appointments for months.

Psychiatrists and PMHNPs are well-positioned to fill this gap, especially for ongoing medication management after diagnosis is confirmed. You already prescribe stimulants for ADHD — the pharmacology overlaps significantly.

Patient Acquisition Reality

Here’s the truth about acquiring narcolepsy patients through traditional marketing:

SEO takes 6-12 months of consistent investment before generating meaningful patient flow. Most solo providers don’t have the expertise or patience for this.

Google Ads for mental health keywords cost $15-40+ per click, and most clicks don’t convert to booked patients. A realistic cost per booked patient through PPC is $200-400+ when you factor in wasted clicks, no-shows from cold leads, and months of testing and optimization.

Directory listings (Psychology Today, Zocdoc) charge monthly fees AND you compete with hundreds of other providers on the same page. Zocdoc charges per booking ($35-100+), but total monthly cost including subscription adds up fast.

When you add up all costs — agency/consultant fees, ad spend, staff time to handle and qualify leads, failed campaigns, no-show rates from cold leads — acquiring a qualified psychiatric patient through DIY marketing typically costs $200-500+.

And that’s if you have the budget, expertise, and patience. Most providers, especially those starting out or scaling, don’t.

The Platform Economics Alternative

This is where a platform like Klarity Health changes the equation.

Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay a standard listing fee per new patient lead (similar to Zocdoc’s pay-per-appointment model).

Key advantages:

• No upfront marketing spend or monthly subscription fees
• Pre-qualified patients already matched to your specialty (narcolepsy/sleep disorders) and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure (no separate platform costs for video, EHR, e-prescribing)
• Both insurance and cash-pay patient flow (you’re not limited to one or the other)
• You control your schedule — only pay when you see patients

The ROI is guaranteed: Every dollar you spend goes toward a patient who actually books with you. Compare that to traditional marketing where you might spend $500 in ad clicks to get one booked appointment (and that patient might still no-show).

For narcolepsy specifically, platforms solve another critical problem: care coordination. Klarity can help connect patients to local sleep labs for diagnostic testing, verify insurance coverage, and handle the administrative burden of multi-state licensing — so you can focus on clinical care.

What Happens When the DEA Waiver Expires?

Let’s game out the scenarios for post-2026.

Most Likely Scenario: Hybrid Requirements

The DEA will probably land on something like:

• Initial 30-day supply via telehealth for new patients
• In-person exam required within 90 days for ongoing Schedule II prescribing
• Established patients can continue via telehealth indefinitely

This would mirror how buprenorphine prescribing works in some states — start remotely, confirm in-person, then manage remotely long-term.

Impact on your practice: You’d need partnerships with local clinics or sleep centers to facilitate that initial in-person visit. Platforms like Klarity could coordinate this (and likely will, given the regulatory trajectory).

Possible Alternative: Special Telemedicine Registration

The DEA has floated the idea of a ‘Telemedicine Special Registration’ that would let qualified clinicians prescribe controlled substances nationwide via telemedicine without in-person exams, subject to certain safeguards.

If this happens, it would be a game-changer — but it hasn’t materialized yet, and there’s no timeline.

Worst-Case Scenario: Full Reversion to Ryan Haight

If the DEA simply lets the waiver expire without new rules, we revert to the pre-COVID requirement: every patient needs an in-person visit before any controlled substance can be prescribed via telemedicine.

This would effectively kill pure telehealth for narcolepsy treatment (at least for stimulants). You’d need brick-and-mortar partnerships or hybrid models in every state.

Likelihood: Low. The political and public health backlash would be enormous, and the DEA knows it. They’ve already committed to permanent rules rather than just ending the flexibilities.

Practical Strategies for Building a Narcolepsy Telehealth Practice Now

Strategy 1: Focus on States with Favorable Rules

If you’re just getting started, target:

• New York (full NP practice, aligned with federal telehealth rules)
• California (NP independence, no state telehealth barriers)
• Illinois (FPA for qualified NPs, no extra restrictions)

Avoid or delay:

• Florida (Schedule II telehealth ban for narcolepsy)
• Texas (NP Schedule II ban)

Get licensed in 2-3 friendly states first, build your patient base, then expand strategically.

Strategy 2: Establish Sleep Lab Partnerships Early

You cannot diagnose narcolepsy purely via telehealth. Start building referral relationships with:

• Local sleep centers in your licensed states
• Hospital sleep labs that accept telehealth referrals
• Independent sleep diagnostic companies

Klarity’s value here: They can negotiate preferred partnerships at scale, rather than you cold-calling sleep centers one by one.

Strategy 3: Use Modafinil as Your First-Line in Restricted States

In Florida and other states with Schedule II telehealth restrictions, lead with modafinil or armodafinil. They’re effective for excessive daytime sleepiness, have lower abuse potential, and aren’t subject to the same telehealth bans.

Reserve Schedule II stimulants for patients who fail modafinil, and coordinate an in-person visit with a local provider to initiate those.

Strategy 4: Document Like Your License Depends On It (Because It Does)

For every narcolepsy patient you treat via telehealth:

• Document the video exam thoroughly — what you observed, mental status, any physical observations you can make remotely
• Note why controlled medication is necessary — prior treatments tried, severity of symptoms, impact on functioning
• Screenshot PDMP checks and note in chart
• Document informed consent for telehealth and controlled substance risks
• Set a monitoring plan — how often you’ll follow up, what red flags would prompt in-person evaluation

State medical boards will audit controlled substance prescribing. You want a chart that shows standard-of-care evaluation, not a rubber-stamp prescription factory.

Strategy 5: Prepare for a Hybrid Future

Even if you start with pure telehealth under the current DEA waiver, assume you’ll eventually need to integrate in-person touchpoints.

Options:

• Require one initial in-person visit before starting Schedule II (conservative, future-proof)
• Partner with local clinics that can do the in-person exam on your behalf (many urgent cares or primary care offices will do this for a fee)
• Use locum tenens or visiting clinics in underserved areas (set up periodic in-person clinic days in your target states)

Platforms can help coordinate this at scale — much easier than you managing it yourself across multiple states.

The Real Talk: Is Narcolepsy Telehealth Worth It?

Short answer: Yes, if you target the right states and build the right partnerships.

Narcolepsy is genuinely underserved. Patients wait months to see specialists, travel hours for appointments, and often settle for primary care providers who aren’t comfortable managing stimulants or sodium oxybate.

If you’re a psychiatrist or PMHNP who’s already prescribing stimulants for ADHD, adding narcolepsy to your scope isn’t a huge clinical leap — but it opens a new patient population with high need and typically good insurance coverage (since narcolepsy is a recognized medical diagnosis, not just mental health).

The regulatory complexity is real, but it’s manageable if you:

• Choose your states strategically
• Use a platform that handles licensing, credentialing, and care coordination
• Build compliance into your workflow from day one

The alternative — trying to build a narcolepsy practice through DIY marketing and piecemeal partnerships — will cost you $3,000-5,000/month in marketing with uncertain ROI, plus hundreds of hours coordinating sleep lab referrals, insurance verification, and multi-state licensing.

A platform like Klarity Health removes that risk entirely. You pay per patient, not per click. Patients come pre-qualified and matched to your availability. The infrastructure (telehealth platform, EHR, e-prescribing, PDMP integration) is built-in. And the care coordination (sleep lab referrals, in-person visit coordination if needed) is handled for you.

That’s guaranteed ROI vs. gambling on marketing channels.

Next Steps

If you’re a psychiatrist or PMHNP interested in treating narcolepsy patients via telehealth:

1. Verify your state allows it — Check the table earlier in this article for your state’s specific rules
2. Get properly credentialed — DEA registration, state licenses, PDMP enrollment, e-prescribing platform
3. Build your knowledge base — Review narcolepsy diagnosis criteria, treatment algorithms, and medication monitoring (AASM guidelines are a good start)
4. Partner with a platform — Unless you want to spend the next 6 months building infrastructure from scratch, join a telehealth platform that already has the patient flow, compliance systems, and care coordination in place

Klarity Health’s provider network is built specifically for this: psychiatrists and PMHNPs who want to expand access to underserved conditions (like narcolepsy) without drowning in regulatory complexity or marketing costs.

You bring the clinical expertise. The platform brings the patients, infrastructure, and compliance support. You control your schedule and only pay when you see patients.

Explore joining Klarity’s provider network to start treating narcolepsy patients in your licensed states — with none of the patient acquisition risk and all of the clinical autonomy.

FAQ: Narcolepsy Telehealth Prescribing

Can I diagnose narcolepsy purely via telehealth?

Not completely. Confirming narcolepsy requires overnight polysomnography and a Multiple Sleep Latency Test (MSLT), which must be done in person at a sleep lab. You can conduct the initial evaluation via video, order the testing, and then make the diagnosis based on results — but you’ll need to coordinate in-person diagnostic studies. Many telehealth providers refer to local sleep centers or partner with hospitals that have sleep labs.

Is prescribing Schedule II stimulants via telehealth legal in 2026?

Yes, under the current DEA waiver (extended through December 31, 2026), you can prescribe Schedule II stimulants for narcolepsy via telehealth without an initial in-person visit — if your state allows it. Florida explicitly bans Schedule II telehealth prescribing for non-psychiatric conditions like narcolepsy. Texas bans NPs from prescribing Schedule II in outpatient settings entirely. Other states (NY, CA, IL, PA) currently permit it under the federal waiver.

What happens when the DEA waiver expires after 2026?

The DEA is working on permanent telehealth prescribing rules. Most likely, they’ll require some in-person component (e.g., initial exam within 90 days, or periodic in-person visits for ongoing Schedule II therapy). Until those rules are finalized, the waiver remains in effect. Providers should prepare for a hybrid model that includes in-person touchpoints, possibly through local clinic partnerships.

Can PMHNPs prescribe narcolepsy medications independently?

It depends on the state. In full practice states (New York, California for qualified NPs, Illinois for FPA-NPs), experienced PMHNPs can diagnose and treat narcolepsy independently, including Schedule II prescribing. In restricted states (Texas, Florida), NPs need physician oversight and face additional limits (Texas NPs can’t prescribe Schedule II at all; Florida NPs are limited to 7-day Schedule II supplies). Pennsylvania requires collaboration but allows Schedule II prescribing with a 30-day limit.

Do I need to check the PDMP every time I prescribe?

Yes, in nearly all states. Most states mandate PDMP checks before each controlled substance prescription (or at minimum, before the first prescription and periodically thereafter). New York, California, Illinois, Texas, Florida, and Pennsylvania all require PDMP queries. Some states (like California) require checking at first prescription and every 4 months during ongoing therapy. Make PDMP integration into your e-prescribing workflow non-negotiable.

Can I use audio-only (phone) for telehealth narcolepsy visits?

Generally no, especially when prescribing controlled substances. Texas explicitly requires two-way audio-visual (live video) for any telehealth visit involving controlled drugs. Most states expect video for establishing a patient relationship and conducting an appropriate exam. Audio-only might be acceptable for established patients in mental health follow-ups in some states, but for narcolepsy medication management involving stimulants, video is the standard.

What’s the best first-line medication for telehealth narcolepsy treatment in restrictive states?

Modafinil or armodafinil (Schedule IV). These aren’t covered by Florida’s Schedule II telehealth ban, can be prescribed by NPs in all states (within scope of practice), and are effective for excessive daytime sleepiness. They’re often first-line treatment anyway due to lower abuse potential compared to amphetamines. Reserve Schedule II stimulants for patients who fail modafinil and coordinate in-person visits for those prescriptions in restrictive states.

References and Sources

1. HHS Press Release – ‘HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026’ – Official announcement of the fourth extension of COVID-era telehealth flexibilities for controlled substances. Published January 2, 2026. www.hhs.gov

2. DEA Press Release – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ – Details on the DEA’s ongoing rulemaking process and temporary extensions. Published November 15, 2024. www.dea.gov

3. 21 U.S.C. §829(e) Ryan Haight Act – Federal law defining in-person medical evaluation requirements for controlled substance prescribing via telemedicine. Cornell Legal Information Institute. www.law.cornell.edu

4. Florida Statutes §456.47 – Use of Telehealth to Provide Services – State law prohibiting Schedule II and III controlled substance prescribing via telehealth except for specified conditions (psychiatric disorders, inpatient, hospice, nursing home). Updated through 2025. www.leg.state.fl.us

5. New York State DOH – Controlled Substances Prescribing via Telehealth Final Rule – Summary of New York’s May 2025 regulations aligning state telehealth controlled substance rules with federal DEA policy. Nixon Peabody law firm analysis, June 18, 2025. [www.nixonpeab

Source:

• https://www.law.cornell.edu/definitions/uscode.php?defid=21-USC-1796173870-113781527&height=800&iframe=true&termoccur=999&term_src=title%3A21%3Achapter%3A13%3Asubchapter%3AI%3Apart%3AC%3Asection%3A831&width=840#:~:text=,that%20a%20prescription%20has%20been
• https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html#:~:text=announced%20a%20fourth%20temporary%20extension,while%20permanent%20rules%20are%20finalized
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=promulgate%20a%20final%20set%20of,Medications%2C%E2%80%9D%20was%20submitted%20to%20the
• https://www.dea.gov/press-releases/2025/12/31/dea-extends-telemedicine-flexibilities-ensure-continued-access-care#:~:text=On%20January%2017%2C%202025%2C%20DEA,to%20as%20the%20%E2%80%9CTwo%20Final
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.tmb.state.tx.us/page/facility-based-prescriptive-delegation#:~:text=at%20the%20hospital%E2%80%99s%20facility,from%20a%20qualified%20hospice%20provider
• https://www.cchpca.org/resources/state-telehealth-laws-and-reimbursement-policies-report-fall-2025/#:~:text=Texas%20regulations%20emphasize%20continuity%20of,Note
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=match%20at%20L114%20The%20rule,and%20the%20US%20Department%20of
• https://www.nixonpeabody.com/insights/alerts/2025/06/18/new-york-state-finalizes-telemedicine-rule-for-controlled-substances#:~:text=In%20short%2C%20the%20exception%20permits,as%20a%20condition%20of%20state
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Conversely%2C%20in%20Restricted%20Practice%20states,expand%20this%20scope%20%206